title: Studies on the T3 suppression test with reference to the thyroidal 123I uptake in Graves' disease: comparison of 24-hour and 3-hour uptake.
abstract: Eighty-three patients with Graves' disease had been treated with methylmercaptoimidazole (MMI). They were prescribed a maintenance dose of antithyroid drug (MMI, 5 mg/day) at the time of a T3 suppression test. The 3-hour and 24-hour thyroidal 123I uptake after T3 administration (75 micrograms/day, 2 weeks) were measured (post T3 uptake). In 38 patients whose post T3 uptake was below 35% in post T3 24-hour uptake, treatment was stopped. The T3 suppression test was then repeated 1 and 3 months later. During a one-year follow up, 26 remained well, while 12 relapsed within 6 to 12 months. We have observed a good correlation between 3-hour uptake and 24-hour uptake of 123I after T3 administration (r = 0.847, p less than 0.001). In 38 patients who showed positive T3 suppression, most patients with MMI withdrawal produced a marked overshoot of post T3 3-hour and 24-hour uptake at one month. Retrospective analysis indicated that there was no significant difference in circulating thyroid hormone levels between remission and relapse groups. The present study provides evidence that 3-hour uptake values are able to be substituted for 24-hour uptake values during a T3 suppression test. In addition, overshoot of thyroidal uptake after antithyroid drug withdrawal was observed in 3-hour values, similar to 24-hour values.
authors: First Department of Internal Medicine, Gunma University School of Medicine, Maebashi, Japan.
authors: T
authors: T
authors: Yamaguchi
authors: I
authors: I
authors: Kobayashi
authors: Y
authors: Y
authors: Yamaguchi
authors: A
authors: A
authors: Iwashita
authors: T
authors: T
authors: Inukai
authors: K
authors: K
authors: Ohshima
authors: Y
authors: Y
authors: Shimomura
authors: S
authors: S
authors: Kobayashi
mesh_terms: D005260:Female; D006111:Graves Disease / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D012008:Recurrence; D012074:Remission Induction / Q000379:methods; D012189:Retrospective Studies; D013960:Thyroid Function Tests / Q000379:methods*; D013997:Time Factors; D014284:Triiodothyronine
chemical_list: D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D008713:Methimazole